BD launches third-generation total lab automation system for microbiology labs

USA – Becton, Dickinson and Company (BD) has launched the new third-generation BD Kiestra Total Lab Automation (TLA) System for microbiology laboratories.

BD Kiestra lab solutions, including scalable and modular microbiology workflow automation solutions, offer total lab automation for the clinical microbiology laboratory. Currently, two companies offer distinct TLA solutions in microbiology: BD-Kiestra and bioMérieux & Copan (WASPLab). The robotic track system is suitable for use with the BD Kiestra microbiology laboratory solution, which automates lab specimen processing.

Designed to meet the evolving requirements of labs, the new robotic track system will enable the formation of a custom and flexible total lab automation configuration that can link several BD Kiestra modules. The workflow can be completely automated, from routine specimen inoculation processes to advanced incubation, imaging, and colony selection for the detection of pathogens.

Using BD Synapsys informatics solution, each step of the lab’s diagnostic pathway can be traced. The solution will help improve laboratory decisionmaking and productivity through integrated workflows and on-demand insights.

USA — Thermo Fisher Scientific has introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution designed to help meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. As part of Cell Therapy Systems (CTS) solutions, the CTS AAV-MAX System is designed to work within the AAV production workflow, from cell culture and transfection through AAV viral vector production.

It is currently the only product of its kind manufactured under cGMP conditions, allowing for large-scale applications. The system can save manufacturers up to 50% on production costs when compared to alternative polyethyleneimine (PEI)-based suspension systems, and it can help reduce plasmid DNA costs by 25%.

It also features a mammalian-based suspension system comprised of a clonal HEK293 cell line and animal originfree reagents that support scalable AAV production from shake flask to bioreactor scale. In addition, the CTS AAV-MAX System allows researchers to seamlessly transition from research on the Gibco AAV-MAX Helper Free AAV Production System to clinical scale.